CALL/GILEAD SCIENCES/140/0.1/20.06.25 | Market Closed - BOERSE MUENCHEN 14:26:31 2024-05-17 EDT | ||
| 0.022 EUR | +69.23% |
|
| Current month | +69.23% | ||
| 1 month | +4.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.022 | +69.23% |
| 24-05-16 | 0.013 | -7.14% |
| 24-05-15 | 0.014 | 0.00% |
| 24-05-14 | 0.014 | +7.69% |
| 24-05-13 | 0.013 | 0.00% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 02:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Goldman Sachs |
| WKN | GG2DVC |
| ISIN | DE000GG2DVC7 |
| Date issued | 2024-01-10 |
| Strike | 140 $ |
| Maturity | 2025-06-20 (397 Days) |
| Parity | 10 : 1 |
| Emission price | 0.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.048 € |
|---|---|
| Lowest since issue | 0.008 € |
| Spread | 0.02 € |
| Spread % | 60.61% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.72
USD
Average target price
82.93
USD
Spread / Average Target
+22.46%
- Stock Market
- Warrants
- Warrant